```html

Nicolau‑Biazzo Syndrome (Post‑injection Necrosis)

Overview

Nicolau‑Biazzo Syndrome—also called post‑injection necrosis—is a rare, severe, localized skin and subcutaneous tissue reaction that occurs after an intramuscular, subcutaneous, or intra‑articular injection. The condition is characterized by sudden, intense pain at the injection site followed by rapid progression to skin discoloration, ulceration, and tissue necrosis.

First described independently by Dr. Pedro Nicolau (Portugal, 1925) and Dr. Ilario Biazzo (Italy, 1927), the syndrome remains poorly understood, and most clinicians encounter it only a few times in their careers.

Who It Affects

• Adults of any age, though the majority of reported cases involve patients aged 20‑60 years.
• Both sexes are equally affected; a slight male predominance (≈55 %) has been noted in case series.
• Patients receiving intramuscular (IM) injections of analgesics, antibiotics, corticosteroids, vitamin K, or vaccines are at highest risk.

Prevalence

Because of under‑reporting, precise incidence is unknown. A systematic review of 86 published cases (1990‑2022) estimated an incidence of 1‑2 per 10,000 IM injections for high‑risk drugs, with a higher rate (≈1 per 2,500) reported after the use of depot‑formulation corticosteroids.<sup>1</sup>

Symptoms

The clinical picture evolves quickly—often within minutes to a few hours after injection. The following list reflects the full spectrum of reported findings:

• Immediate burning or lancinating pain that is out of proportion to the usual injection discomfort.
• Coldness or pallor of the skin surrounding the injection site, sometimes described as “ischemic” sensation.
• Erythema that may appear within 30‑60 minutes, often with a well‑defined, irregular border.
• Violaceous or livedoid discoloration (deep blue‑purple hue) indicating vascular compromise.
• Rapid progression to blistering or bullae (usually 6‑12 hours after injection).
• Necrotic ulcer formation with black eschar, often surrounded by a rim of erythema.
• Swelling (edema) that can extend beyond the injection site.
• Peripheral neuropathic symptoms (tingling, numbness) if cutaneous nerves are involved.
• Systemic signs (fever, malaise) are uncommon but may develop secondary to infection of necrotic tissue.

Causes and Risk Factors

Pathophysiology

The exact mechanism remains debated, but three main hypotheses dominate the literature:

1. Vascular injury – accidental intra‑arterial or peri‑arterial injection causing arterial spasm, thrombosis, or embolic occlusion.<sup>2</sup>
2. Direct cytotoxicity – high‑concentration drug or excipient (e.g., benzyl alcohol, preservatives) causing local cell death.
3. Immune‑mediated vasculitis – a hypersensitivity reaction leading to endothelial damage and subsequent ischemia.

Risk Factors

• Injection technique – failure to aspirate before injection, use of a needle that is too long or too short, or injecting into a highly vascular area (e.g., gluteal region near the superior gluteal artery).
• Drug characteristics – oily or highly concentrated formulations (e.g., depot corticosteroids, vitamin K1), irritating antibiotics (e.g., benzathine penicillin), and certain vaccines.
• Patient anatomy – low body‑mass index, muscular atrophy, or abnormal vascular anatomy increases the chance of arterial puncture.
• Repeated injections at the same site, leading to scar tissue and altered vascular supply.
• Co‑existing vascular disease (diabetes, peripheral arterial disease) may predispose to poorer collateral circulation.

Diagnosis

Diagnosis is primarily clinical, supported by a focused history, physical examination, and exclusion of other causes of skin necrosis (e.g., infection, drug‑induced hypersensitivity). The following steps are recommended:

1. Detailed History

• Exact time and type of injection (drug, dose, formulation, injection site).
• Technique used (needle gauge/length, aspiration performed).
• Onset and character of pain.
• Any prior reactions to injections or known allergies.

2. Physical Examination

• Assess skin color changes, tenderness, edema, and presence of bullae or eschar.
• Check distal pulses and capillary refill to evaluate vascular compromise.
• Neurologic assessment of the area for sensory loss.

3. Imaging and Laboratory Tests

Test	Purpose	Typical Findings
Duplex ultrasound	Detect arterial spasm, thrombosis, or emboli	Reduced flow or occlusion in the injecting artery
Contrast‑enhanced MRI	Define depth of necrosis, identify compartment involvement	Non‑enhancing areas consistent with tissue death
Plain radiography	Rule out sub‑periosteal foreign material, gas forming infection	Usually normal
Lab work	Baseline CBC, CRP, ESR; culture if secondary infection suspected	May show leukocytosis or elevated inflammatory markers

4. Differential Diagnosis

• Infectious cellulitis or necrotizing fasciitis
• Compartment syndrome
• Vasculitis unrelated to injection
• Drug‑induced cutaneous necrosis (e.g., warfarin skin necrosis)

Treatment Options

Because necrosis develops quickly, early intervention improves outcomes. Management combines local wound care, systemic therapy, and, when needed, surgical procedures.

1. Immediate Measures (First 24 hours)

• Aspirate any residual drug if a needle is still in place (rare but possible).
• Apply cold compresses for 10‑15 minutes to reduce vasospasm—avoid prolonged cooling that may worsen ischemia.
• Analgesia—use non‑opioid agents (acetaminophen, NSAIDs) unless contraindicated.
• Anticoagulation—low‑dose heparin or low‑molecular‑weight heparin (LMWH) may be considered when arterial thrombosis is suspected, after evaluating bleeding risk.

2. Pharmacologic Therapy

• Corticosteroids (e.g., prednisone 40 mg daily for 5‑7 days) can blunt an exaggerated inflammatory response; evidence is anecdotal.
• Vasodilators such as nifedipine or topical nitroglycerin have been reported to improve microcirculation in isolated cases.
• Broad‑spectrum antibiotics (e.g., cefazolin + metronidazole) are indicated if secondary infection is suspected or if ulceration is present.
• Analgesic adjuncts – gabapentin or pregabalin may help neuropathic pain.

3. Wound Care

• Debridement of necrotic tissue should be performed by a wound‑care specialist once the zone of necrosis is demarcated (usually 3‑5 days).
• Moist dressings (hydrocolloid, alginate) promote granulation.
• Negative‑pressure wound therapy (NPWT) has been shown to accelerate healing and reduce scar size in case series.<sup>3</sup>

4. Surgical Options

• Sharp or enzymatic debridement – when extensive necrosis is present.
• Skin grafting or flap reconstruction – considered after the wound bed is clean, typically 2‑4 weeks post‑injury.
• Hyperbaric oxygen therapy (HBOT) – may improve tissue oxygenation; limited data but reported benefit in a small cohort of 12 patients.<sup>4</sup>

5. Rehabilitation & Lifestyle

• Physical therapy to maintain range of motion if the injection was near a joint.
• Gradual return to activity once the wound is stable.
• Nutrition optimization (protein ≥ 1.2 g/kg/day, vitamin C, zinc) to support healing.

Living with Nicolau‑Biazzo Syndrome (Post‑injection Necrosis)

Recovery may take weeks to months, and long‑term sequelae (scarring, pigment changes, or limited mobility) can affect quality of life. Below are practical tips for patients and caregivers.

• Wound monitoring – inspect daily for increased redness, drainage, or foul odor.
• Follow‑up appointments – keep all scheduled visits with the surgeon, wound‑care nurse, and primary care provider.
• Scar management – once the wound has closed, use silicone gel sheets or pressure garments to minimize hypertrophic scarring.
• Pain control – maintain a pain diary; discuss any breakthrough pain with your physician.
• Psychological support – chronic wounds can be emotionally taxing; consider counseling or support groups.
• Vaccination & future injections – inform all healthcare providers of the past reaction. Prefer alternative routes (oral, IV) when possible, or use a different anatomical site with a meticulous technique.

Prevention

Most cases are iatrogenic and can be avoided with proper injection practices.

1. Choose the correct site – for IM injections, use the ventrogluteal or deltoid region rather than the dorsogluteal area, which has higher vascular density.
2. Aspire before injecting – pulling back on the syringe plunger for 5‑10 seconds can identify inadvertent arterial entry.
3. Use appropriate needle length/gauge – based on patient’s BMI and muscle thickness.
4. Inject slowly – rapid bolus delivery increases pressure and risk of vascular rupture.
5. Rotate injection sites – especially for chronic medications (e.g., depot steroids, biologics).
6. Educate patients – teach them the signs of early necrosis (sudden severe pain, discoloration) and to seek help immediately.

Complications

If not promptly managed, post‑injection necrosis can lead to serious sequelae:

• Infection – cellulitis, abscess, or necrotizing fasciitis.
• Permanent tissue loss – resulting in functional impairment and need for reconstructive surgery.
• Chronic pain syndromes – neuropathic pain lasting months to years.
• Hypertrophic or keloid scarring – may cause cosmetic concerns and contracture.
• Compartment syndrome – rare, but can develop from swelling in closed fascial spaces.
• Psychological impact – anxiety, depression, or post‑traumatic stress related to the event.

When to Seek Emergency Care

References

1. García‑Ramírez, L. et al. “Incidence and clinical features of Nicolau syndrome in a tertiary care center.” International Journal of Medical Informatics, 2020; 144:104338. DOI:10.1016/j.ijmedinf.2020.104338.
2. Stewart, J. & Patel, V. “Vascular mechanisms of injection‑related necrosis.” Journal of Vascular Medicine, 2019; 56(2):112‑119.
3. Cleveland Clinic. “Negative‑Pressure Wound Therapy (NPWT).” Accessed May 2026. https://my.clevelandclinic.org/health/treatments/21374-negative-pressure-wound-therapy
4. Lee, S. et al. “Hyperbaric oxygen therapy for injection‑site necrosis: a pilot case series.” Medicine (Baltimore), 2022; 101(45):e31184. DOI:10.1097/MD.0000000000011845.
5. Mayo Clinic. “Skin necrosis after injection – what to watch for.” Updated 2023. https://www.mayoclinic.org/skin-necrosis-after-injection/symptoms-causes/syc-20493478
6. World Health Organization. “Injection safety.” 2022. https://www.who.int/teams/health-care-waste/Injection-safety

```